在传统化疗中，由于多药耐药性（MDR）现象，癌细胞可以变得高度有弹性。化疗药物与基于新型纳米载体的靶向 DDS 的共同递送可能会解决 MDR 问题，并随后提高其治疗效果。与此相一致，目前的工作涉及开发基于一维氧化石墨烯纳米卷（GONS）的纳米递送系统，用于共同递送化学增敏剂和化疗剂。在此，一维 GONS 纳米载体最初用壳聚糖 (CS) 生物聚合物和叶酸 (FA) 进行功能化，以进一步增强其生物相容性和目标特异性共递送。所得的 GONS-CS-FA (GCF) 纳米载体与纳米载体和药物成分不同重量比例的阿霉素 (DOX) 和咖啡酸 (CA) 共同负载。当GCF：药物比例为2.5且药物组成为1:1时，观察到最佳装载效率为51.14±1.47%（DOX）和49.70±1.19%（CA）。 pH5 下的体外释放产生了约 83% DOX 和 75% CA，而 pH7.4 下 7 天的体外释放产生了约 71% DOX 和 61% CA，这表明在癌症微环境中具有更高的靶向药物释放。细胞毒性测试显示癌细胞 (A549) 选择性凋亡，同时保持与正常细胞 (HEK293) 的细胞相容性。版权所有 © 2024。由 Elsevier B.V. 出版。

In conventional chemotherapy, the cancer cells can become highly resilient due to a phenomenon known as multi-drug resistance (MDR). The co-delivery of chemotherapeutic agents assisted with novel nanocarrier-based targeted DDS may counter the MDR issues and subsequently improve their therapeutic efficacy. In line with this, the present work deals with the development of 1D graphene oxide nanoscrolls (GONS)-based nano delivery system for co-delivery of chemosensitizer along with the chemotherapeutic agent. Herein, the 1D GONS nanocarrier was initially functionalized with chitosan (CS) biopolymer and folic acid (FA) further to enhance their biocompatibility and target-specific co-delivery. The resultant GONS-CS-FA (GCF) nanocarriers were co-loaded with doxorubicin (DOX) and caffeic acid (CA) at different weight proportions with respect to nanocarrier and drug composition. The optimum loading efficiency of 51.14 ± 1.47 % (DOX) and 49.70 ± 1.19 % (CA) was observed for GCF: drug ratio of 2.5 with drug composition of 1:1. In vitro release at pH 5 yielded ~83 % DOX and 75 % CA, compared to ~71 % DOX and 61 % CA at pH 7.4 over 7 days, suggesting a higher and targeted drug release in the cancer microenvironment. Cytotoxicity tests revealed selective apoptosis in cancer cells (A549) while maintaining cytocompatibility with normal cells (HEK293).Copyright © 2024. Published by Elsevier B.V.